Slaying SARS-CoV-2 One (Single-domain) Antibody at a Time

Area of Science:

• Immunology
• Virology
• Biotechnology

Background:

• The novel coronavirus, SARS-CoV-2, poses a significant global health threat.
• Single-domain antibodies (sdAbs) are small, stable immunoglobulin fragments with high binding affinities.
• sdAbs offer potential therapeutic advantages due to their unique properties.

Purpose of the Study:

• To review recent advancements in identifying and engineering potent sdAbs against SARS-CoV-2.
• To highlight the efficacy of sdAbs targeting the Spike protein's receptor-binding domain (RBD).
• To discuss the potential applications of these sdAbs in the context of the COVID-19 pandemic.

Main Methods:

• Utilizing phage and yeast surface-display technologies for sdAb library screening.
• Isolating rare sdAbs with high affinity and specificity from diverse antibody libraries.
• Engineering sdAbs to enhance binding characteristics and biodistribution.

Main Results:

• Identification of ultrapotent sdAbs specifically targeting the SARS-CoV-2 Spike protein RBD.
• Demonstration of subnanomolar binding affinities for selected sdAbs.
• Potential for engineered sdAbs with improved therapeutic properties.

Conclusions:

• Camelid-derived and synthetic sdAbs are powerful tools against SARS-CoV-2.
• Targeting the Spike protein RBD with sdAbs is a promising therapeutic strategy.
• Further development of sdAbs could significantly contribute to managing COVID-19.